

## **Clinical trial on amisulpride and risperidone in schizophrenia in collaboration with National Institute of Mental Health, Dhaka**

Given the dire and unmet clinical need of patients presenting with negative symptoms in schizophrenia, for the first time in Bangladesh, BAP initiated a randomized clinical trial of amisulpride and risperidone in schizophrenia in collaboration with National Institute of Mental Health (NIMH), Dhaka, Bangladesh from October 2022. The outcomes of these study will help the clinicians to take better evidence-based decision in treating patients with negative symptoms.

This research study seeks to learn how effective are amisulpride and risperidone in patients with schizophrenia having predominantly negative symptoms. We are recruiting males and females aged between 18-45 to participate in this research at NIMH. Treatment and follow up service is available for over 12-weeks with consent of patients with guardians who agreed to join the trial.